Acute Effects of Cyclosporin and Cremophor EL on Endothelial Function and Vascular Smooth Muscle in the Isolated Rat Heart

Overview

Journal Cardiovasc Drugs Ther

Specialties Cardiology & Vascular Diseases
Pharmacology

Date 1992 Feb 1

PMID 1576098

Authors

P Mankad

J Spatenka

Z Slavik

G ONeil

A Chester

M Yacoub

Affiliations

Soon will be listed here.

Abstract

We studied the effects of cyclosporin dissolved in the vehicle used as an intravenous preparation, namely, cremophor EL, and cremophor alone on the basal coronary flow plus endothelial function and vascular smooth muscle response by examining their influence on 5-hydroxytryptamine (5-HT) and nitroglycerine (GTN) induced the changes in coronary flow in the isolated rat heart. A total of 72 rat hearts were perfused with a modified Langendorf preparation. There was a 12.8 +/- 3% reduction in the basal coronary flow after 60 minutes of perfusion with the drug-free buffer (p = ns). A dose of 50 ng/ml of cremophor or cyclosporin gave a similar reduction in the flow (cremophor 9.2 +/- 0.7%, cyclosporin 12.7 +/- 2%). However, at higher concentrations cremophor caused dose-dependent coronary vasodilation, while cyclosporin had the opposite effect. The maximum effect after 1000 ng/ml of cyclosporin was a 48.7 +/- 0.6% decrease, and after an equivalent dose of cremophor a 24.8 +/- 2.2% increase in the flow. The vasodilatory response to 5-HT and GTN remained unchanged after 60 minutes of perfusion with the drug-free buffer (5-HT, before 33.3 +/- 2.5%, after 37.7 +/- 4.2%; GTN, before 34.3 +/- 2.5%, after 33.7 +/- 1.5%).(ABSTRACT TRUNCATED AT 250 WORDS)

References

Macris M, Frazier O, Van Buren C, Lammermeier D, Kahan B . Improved immunosuppression for heart transplant patients using intravenous doses of cyclosporine. Transplantation. 1989; 47(2):311-4. DOI: 10.1097/00007890-198902000-00024. View

Lorenz W, SCHMAL A, Schult H, Lang S, Ohmann C, Weber D . Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: analysis of various components in cremophor El and development of a compound with reduced toxicity. Agents Actions. 1982; 12(1-2):64-80. DOI: 10.1007/BF01965109. View

Bossaller C, Forstermann U, Hertel R, Olbricht C, Reschke V, Fleck E . Ciclosporin A inhibits endothelium-dependent vasodilatation and vascular prostacyclin production. Eur J Pharmacol. 1989; 165(1):165-9. DOI: 10.1016/0014-2999(89)90785-1. View

Bellet M, Cabrol C, Sassano P, Leger P, Corvol P, Menard J . Systemic hypertension after cardiac transplantation: effect of cyclosporine on the renin-angiotensin-aldosterone system. Am J Cardiol. 1985; 56(15):927-31. DOI: 10.1016/0002-9149(85)90406-0. View

Shulman H, Striker G, Deeg H, Kennedy M, Storb R, Thomas E . Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury. N Engl J Med. 1981; 305(23):1392-5. DOI: 10.1056/NEJM198112033052306. View

. Renal histopathology in kidney transplant recipients immunosuppressed with cyclosporin A: results of an international workshop. Clin Nephrol. 1985; 24(3):107-19. View

Lamping K, Marcus M, Dole W . Removal of the endothelium potentiates canine large coronary artery constrictor responses to 5-hydroxytryptamine in vivo. Circ Res. 1985; 57(1):46-54. DOI: 10.1161/01.res.57.1.46. View

Rossi N, Churchill P, McDonald F, Ellis V . Mechanism of cyclosporine A-induced renal vasoconstriction in the rat. J Pharmacol Exp Ther. 1989; 250(3):896-901. View

Radomski M, Palmer R, Moncada S . The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol. 1987; 92(3):639-46. PMC: 1853691. DOI: 10.1111/j.1476-5381.1987.tb11367.x. View

10.

Dinh Xuan A, Fan T, Higenbottam T, Wallwork J . Cyclosporine in vitro reduces endothelium-dependent relaxation to acetylcholine but does not affect relaxation to nitrovasodilators. Transplant Proc. 1990; 22(4):1723-5. View

11.

Rego A, Vargas R, Wroblewska B, Foegh M, RAMWELL P . Attenuation of vascular relaxation and cyclic GMP responses by cyclosporin A. J Pharmacol Exp Ther. 1990; 252(1):165-70. View

12.

Besarab A, Jarrell B, Hirsch S, Carabasi R, Cressman M, Green P . Use of the isolated perfused kidney model to assess the acute pharmacologic effects of cyclosporine and its vehicle, cremophor EL. Transplantation. 1987; 44(2):195-201. DOI: 10.1097/00007890-198708000-00005. View

13.

ONeil G, Chester A, Rose M, Tadjkarimi S, Yacoub M . The effect of cyclosporine on the release of endothelium-derived relaxing factor from isolated human epicardial coronary arteries. Transplantation. 1991; 51(3):736-8. View

14.

Kon V, Sugiura M, Inagami T, Harvie B, Ichikawa I, Hoover R . Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int. 1990; 37(6):1487-91. DOI: 10.1038/ki.1990.139. View

15.

Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y . A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 332(6163):411-5. DOI: 10.1038/332411a0. View

16.

McKenzie N, Devineni R, Vezina W, Keown P, Stiller C . The effect of cyclosporine on organ blood flow. Transplant Proc. 1985; 17(4):1973-5. View

17.

Griffith T, Lewis M, Newby A, Henderson A . Endothelium-derived relaxing factor. J Am Coll Cardiol. 1988; 12(3):797-806. DOI: 10.1016/0735-1097(88)90324-5. View

18.

Bassenge E, Busse R . Endothelial modulation of coronary tone. Prog Cardiovasc Dis. 1988; 30(5):349-80. DOI: 10.1016/0033-0620(88)90003-5. View

19.

Whiting P, Thomson A, Simpson J . Cyclosporine: toxicity, metabolism, and drug interactions--implications from animal studies. Transplant Proc. 1985; 17(4 Suppl 1):134-44. View

20.

Saldanha C, Hearse D . Coronary vascular responsiveness to 5-hydroxytryptamine before and after infusion of hyperkalemic crystalloid cardioplegic solution in the rat heart. Possible evidence of endothelial damage. J Thorac Cardiovasc Surg. 1989; 98(5 Pt 1):783-7. View